Pfizer has completed the acquisition of Metsera, a biotech firm focused on anti-obesity and cardio-metabolic disease drugs.[2][6] The deal is valued at approximately $4.9 billion up front, plus potential additional payments, for a total of up to $7.3 billion.[1][2][3] Thus, Pfizer acquired the experimental drug MET-097i, a monthly or weekly injection of a GLP-1 receptor agonist, which achieved an 11.3% weight loss over 12 weeks in a mid-stage clinical trial.[1][3][4][6] This candidate is about to enter the third phase of development.[6] Another candidate, MET-233i, is a monthly amylin analogue in phase one development, either as monotherapy or in combination with MET-097i.[6] In addition, Metsera is developing an oral GLP-1 receptor agonist in Phase I and other preclinical products.[6] The acquisition follows the failure of Pfizer's own candidate danuglipron in clinical trials.[1][4] These candidates complement Pfizer's internal medicine offering.[6]